On October 3, 2025 HanchorBio, a clinical-stage biotechnology company focusing on immune-oncology and dedicated to developing next-generation multi-specific immunotherapies, reported that an abstract detailing preclinical data on HCB301, the company’s novel tri-specific anti-cancer fusion protein, has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 40th Anniversary Annual Meeting (Press release, Hanchor Bio, OCT 3, 2025, View Source [SID1234656428]). The meeting will take place from November 5 to 9, 2025, in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Acceptance for a poster presentation at the SITC (Free SITC Whitepaper) Annual Meeting underscores the scientific rigor and innovation behind HCB301’s development. SITC (Free SITC Whitepaper) is the world’s largest annual conference solely dedicated to cancer immunotherapy. Each year, more than 1,300 abstracts are submitted, evaluated according to rigorous selection criteria based on research quality, novelty, and their potential to advance cancer immunotherapy.

Presentation Details

The accepted abstract, titled "A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGFβ Remodels the Tumor Microenvironment and Enhance Anti-Tumor Immunity", will be presented on Saturday, November 8, 2025. The presentation will highlight preclinical efficacy and safety data supporting HCB301’s potential as a first-in-class immune-enhancing biologic that targets key mechanisms of tumor immune evasion.

"We are honored to present these compelling preclinical data at SITC (Free SITC Whitepaper) 2025," said Wenwu Zhai, Chief Scientific Officer of HanchorBio. "HCB301 exemplifies the power of our FBDB platform to rationally design multi-specific biologics that restore immune activity and deliver enhanced anti-tumor responses."

About HCB301

HCB301 is a tri-functional IgG4 Fc fusion protein that incorporates:

An anti-PD-L1 antibody,
A high-affinity SIRPα variant to disrupt CD47-mediated "don’t eat me" signaling, and
A TGF-βRII trap domain.
Following successful preclinical development, HCB301 is now in a Phase 1 multi-regional clinical trial in the U.S. and Taiwan to evaluate its safety, tolerability, and anti-tumor activity in patients with advanced solid tumours.

In preclinical studies, HCB301 demonstrated:

Potent blockade of PD-L1 and TGF-β signaling,
Robust phagocytosis of CD47+ tumor cells in vitro with minimal red blood cell binding, suggesting an improved hematologic safety profile compared to CD47-targeting analogs, and
In vivo efficacy comparable to a triple-agent cocktail across multiple xenograft models.
The abstract will also be published in the Journal for ImmunoTherapy of Cancer (JITC) in February 2026 as part of the SITC (Free SITC Whitepaper) 2025 Final Supplement.

On October 3, 2025 Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, reported two upcoming presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting, taking place in National Harbor, Md., Nov. 5-9, 2025 (Press release, Dispatch Bio, OCT 3, 2025, View Source [SID1234656429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors
Abstract: 393
Primary Category: Cellular Therapies
Poster Presentation Day: Friday, Nov. 7
Presenter: Lisa Cucolo, Ph.D., Senior Scientist at Dispatch

Title: Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment
Abstract: 394
Primary Category: Cellular Therapies
Poster Presentation Day: Saturday, Nov. 8
Presenter: Raymond Liu, Ph.D., Co-Founder and Head of Synthetic Biology at Dispatch

On October 2, 2025 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany (Press release, Hutchison China MediTech, OCT 2, 2025, View Source [SID1234656377]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions.

Details of the presentations are as follows:

Abstract titlePresenter / Lead authorPresentation details

SPONSORED STUDIES
Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2) Zhenhua Liu
(Chengdu, China) 2592MO
Mini Oral Session 1:
GU tumours, renal & urothelial
Friday, Oct 17, 2025
Karlsruhe Auditorium – Hall 5.2
16:00 – 17:30 CEST
A Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC) Stefan Kasper-Virchow
(Essen, Germany) 794P
Poster Session:
Colorectal cancer
Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 study N. Arvind Dasari
(Houston, USA) 799P
Poster Session:
Colorectal cancer
A novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC) Sara Lonardi
(Padua, Italy) 804P
Poster Session:
Colorectal cancer
Safety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancer Cathy Eng
(Nashville, USA) 811P
Poster Session:
Colorectal cancer
Association between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 study Danbo Wang
(Shenyang, China) 1230eP
Poster Session:
Gynaecological Cancer
ctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI) Yongfeng Yu
(Shanghai, China) 1954P
Poster Session:
NSCLC, metastatic
SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi Quincy Siu-chung Chu
(Edmonton, Canada) 1955P
Poster Session:
NSCLC, metastatic
MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) study Julia Rotow
(Boston, USA) 1956P
Poster Session:
NSCLC, metastatic

INVESTIGATOR-INITIATED STUDIES
Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trial Fei Ma
(Zhengzhou, China) 2159P
Poster Session: Oesophagogastric cancer
Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II Study Wangjun Liao
(Guangzhou, China) 898eP
E-poster Session:
Colorectal cancer
The efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical study Qianqian Wang
(Nanjing, China) 929P
Poster Session:
Developmental therapeutics
Surufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination Regimens Yanfang Zheng
(Guangzhou, China) 1884P
Poster Session:
NSCLC, metastatic
Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase ll Results from a Single-Center Trial Wenfeng Fang/ Li Zhang
(Guangzhou, China) 1887P
Poster Session:
NSCLC, metastatic
Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancer Song Gao/ Jihui Hao
(Tianjin, China) 2236P
Poster Session:
Pancreatic cancer
Efficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II Study Xiaowei Zhang/ Zhiguo Luo (Shanghai, China) 2716P
Poster Session:
Sarcoma

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ("VEGFR") -1, ‑2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA.

About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS.

About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA. HUTCHMED currently retains all rights to surufatinib worldwide.

On October 2, 2025 Biosceptre International Limited reported the successful completion of its 2025 fundraise, securing £8.1 million through the issue of 40,500,000 new shares (Press release, Biosceptre, OCT 2, 2025, View Source;utm_medium=rss&utm_campaign=biosceptre-secures-8-1-million-to-accelerate-innovative-cancer-therapies [SID1234656397]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This achievement underscores the strong confidence of investors in Biosceptre’s pioneering approach to developing novel treatments for hard-to-treat cancers.

Biosceptre CEO Gavin Currie commented:

"This fundraise marks an important milestone for Biosceptre as we accelerate the development of our therapeutic pipeline. With the continued support of our investors, we are advancing towards our vision of bringing transformative treatments to patients worldwide. Our team is deeply committed to tackling some of the most pressing challenges in oncology and to building a future where patients have access to more effective and targeted therapies."

With this new capital in place, Biosceptre will continue to progress its therapeutic pipeline and deliver on key milestones in the months ahead.

The newly issued shares are scheduled to be dispatched by 8th October 2025.

On October 2, 2025 Ataraxis AI, a frontier laboratory developing artificial intelligence (AI)–powered prognostic tools for oncology, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, reported a strategic collaboration to integrate artificial intelligence into multiple major international trials (Press release, MedSIR, OCT 2, 2025, View Source [SID1234656415]). These studies, involving data from more than 1,000 patients across randomized clinical trials, aim to identify biomarkers that can optimize treatment strategies for breast cancer, including therapies with CDK4/6 inhibitors and antibody-drug conjugates (ADCs).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MEDSIR has been a key contributor to oncology clinical trials, helping support the advancement of transformative therapies into standard practice. These efforts have expanded access to novel treatment options and improved outcomes for patients worldwide. The introduction of new therapeutics creates an opportunity but also a challenge to select the right drug for every patient. Ataraxis addresses this critical need with Ataraxis Breast, the first AI-native platform in breast cancer developed to predict patient outcomes and treatment effects. By integrating insights from standard digital pathology slides with clinical data, the platform provides a new evidence-based layer to support treatment decisions and personalize care.

Building upon Ataraxis’ previous positive clinical validation results showing efficacy across major breast cancer subtypes, the research collaboration between MEDSIR and Ataraxis AI will focus on leveraging artificial intelligence to predict outcomes across key breast cancer subtypes—including HR+ and HER2+ cohorts—encompassing patients in early-stage and metastatic settings. The goal is to enhance clinical decision-making by integrating AI-driven insights into routine oncology workflows.

"Breast cancer treatment continues to improve, with new therapies becoming available every year. However, this creates a challenge in selecting the right drug at the right time. At Ataraxis, we are developing AI-native tools to accurately predict patient outcomes and treatment response for all cancer patients. We are proud to partner with MEDSIR to validate our breast cancer platform using data from practice-changing clinical trials," said Jan Witowski, Chief Executive Officer and Co-Founder of Ataraxis AI.

"At MEDSIR, we are committed to accelerating innovation in oncology through collaborative research that brings real value to patients and clinicians," said Alicia García, Scientific Director at MEDSIR. "Partnering with Ataraxis AI allows us to integrate cutting-edge artificial intelligence into clinical trials, generating evidence that can transform treatment decision-making in breast cancer. This collaboration represents an important step toward a future where precision oncology is not just a concept, but a standard of care."

This announcement demonstrates the commitment to building global collaborative networks for both MEDSIR and Ataraxis AI. With strategic headquarters in Europe and the United States, MEDSIR has built an extensive global network of more than 600 researchers and has conducted 65 clinical trials across more than 200 sites in 14 countries. Ataraxis AI has partnerships with over 40 institutions on the development, validation, and deployment of AI-based tools for treatment selection. Additionally, this collaboration marks a milestone in building clinical evidence for Ataraxis Breast moving beyond retrospective observational studies and into prospective trials investigating new therapies.